Cases & Deals

  • Home
  • Practices
  • Celgene announces dismissal of suit against Barr Laboratories following withdrawal of thalidomide ANDA

Share

Celgene announces dismissal of suit against Barr Laboratories following withdrawal of thalidomide ANDA

May 2010

Client(s) Celgene Corporation

Jones Day successfully represented Celgene Corporation in a Hatch-Waxman patent litigation against Barr Laboratories, Inc., in connection with Celgene's brand thalidomide product, Thalomid®. In May 2010, Barr withdrew its Abbreviated New Drug Application (ANDA) for thalidomide with the US Food and Drug Administration. As a result of Barr's withdrawal, the US District Court for the District of New Jersey has granted the parties' requested dismissal of all claims, including the dismissal with prejudice of Barr's patent and antitrust counterclaims.

Celgene Corp. et al. v. Barr Labs, Inc., Civil Action No. 2-07-00286 (D. N.J.)

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.